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ABSTRACT
The identification of upper tract urinary carcinoma (UTUC) prognostic biomarkers 
is urgently needed to predict tumour progression. This study aimed to identify serum 
microRNAs (miRNAs) that may be useful as minimally invasive predictive biomarkers 
of tumour progression and survival in UTUC patients. To this end, 33 UTUC patients 
who underwent radical nephroureterectomy at the Hospital Clinic of Barcelona were 
prospectively included. Expression of 800 miRNAs was evaluated in serum samples 
from these patients using nCounter® miRNA Expression Assays. The study was 
divided into an initial discovery phase (n=12) and a validation phase (n=21). Cox 
regression analysis was used for survival analysis. The median follow-up (range) of 
the series was 42 months (9-100 months). In the discovery phase, 38 differentially 
expressed miRNAs were identified between progressing and non-progressing UTUC 
patients (p<0.05). Validation of these 38 miRNAs in an independent set of UTUC 
patients confirmed the differential expression in 18 of them (p<0.05). Cox Regression 
analysis showed miR-151b and pathological stage as significant prognostic factors 
for tumour progression (HR=0.33, p<0.001 and HR=2.62, p=0.006, respectively) and 
cancer specific survival (HR=0.25, p<0.001 and HR=3.98, p=0.003, respectively). 
Survival curves revealed that miR-151b is able to discriminate between two groups 
of UTUC patients with a highly significant different probability of tumour progression 
(p=0.006) and cancer specific survival (p=0.034). Although the data needs to be 
externally validated, miRNA analysis in serum appears to be a valuable prognostic 
tool in UTUC patients. Particularly, differential expression of miR-151b in serum may 
serve as a minimally invasive prognostic tool in UTUC.
INTRODUCTION
Radical nephroureterectomy (RNU) is the 
accepted treatment for localized upper tract urinary 
carcinoma (UTUC) [1]. Pathological stage and 
tumour grade are the most established prognostic 
factors associated with tumour progression and 
patient survival, but they are insufficient to predict 
the individual outcome of UTUC patients [2]. More 
accurate knowledge regarding the biological behaviour 
of tumours would allow for tailored treatment 
schedules to be offered to patients (such as neodjuvant 
chemotherapy or early radical surgery), in an attempt to 
increase survival and decrease morbidity.
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The rapid advance in the understanding of the 
molecular biology of UTUC has led to the appearance of 
promising new biomarkers such as microRNAs (miRNAs) 
[3–6]. miRNAs are an abundant class of newly identified 
endogenous non-protein-coding small RNAs with a 20-
25 nucleotide length [7], which can negative-regulate 
protein expression of target genes. Recent studies show that 
several miRNAs are differentially expressed in different 
human cancers, which indicate that miRNAs may have a 
role in the carcinogenetic processes of numerous tumours 
[8–11]. Interestingly, these miRNA differences have also 
been observed in human biofluids [12, 13]. It has been 
recently demonstrated that circulating miRNAs in the 
blood stream are present in a stable and reproducible state 
[14]. Moreover, blood samples are easily acquired in a 
relatively non-invasive manner and miRNAs from blood 
can be readily detected [15]. Notably, the serum miRNA 
expression profile has been used as a fingerprint for various 
malignancies, including carcinomas of the urinary tract 
[13, 16]. In particular, diagnostic miRNAs in serum have 
been described for UTUC [17]. However, to the best of 
our knowledge, the prognostic global circulating miRNA 
patterns from UTUC patients have not been studied as yet.
In the present work, we aim to determine the 
differential miRNA expression patterns in serum of 
progressing and non-progressing UTUC patients in 




Median age (range) of the series was 70 (53-90) 
years. The median (range) follow-up of the cohort was 
42 (9-100) months. Tumour progression was documented 
in 13 patients (39%). The median (range) time of tumour 
progression was 10 (2-46) months. Eleven patients (33%) 
died due to their UTUC. The median (range) time of cancer 
specific death was 24 (6-48) months. Two patients with 
tumour progression died from diseases other than UTUC.
Discovery phase
Overall, 38 miRNAs were identified as differentially 
expressed between progressing (n=5) and non-progressing 
(n=7) UTUC patients. Of these, nine miRNAs were up-
regulated and 29 down-regulated in progressing patients. 
A heat map based on the differentially expressed miRNAs 
between the two groups of UTUC patients is shown in Figure 1.
Validation phase
All 38 miRNAs previously identified as 
differentially expressed were analyzed in an independent 
set of 21 UTUC serum samples (8 progressing and 13 non-
progressing). Eighteen microRNAs remained differentially 
expressed between these two groups of UTUC patients; 
all of them were down-regulated in progressing patients 
(Table 1).
Survival analysis
Multivariate Cox regression analysis including 
clinical covariates and serum expression levels of the 18 
differentially expressed miRNAs showed that miR-151b 
and pathological stage were significant prognostic factors 
for tumour progression (HR=0.33; p<0.001 and HR=2.62; 
p=0.006, respectively) and cancer specific survival 
(HR=0.25; p<0.001 and HR=3.98; p=0.003, respectively).
Thereafter, the median expression value of miR-
151b was used as a cut-off point to classify patients into 
a high-risk group (61%) and a low-risk group (39%) for 
tumour progression. Figure 2 depicts Kaplan-Meier curves 
generated using the selected cut-off point. As shown, the 
miR-151b expression value was able to discriminate 
between two groups of UTUC patients with a highly 
significant different probability of tumour progression 
(p=0.006) and cancer specific survival (p=0.034).
Pathway analysis
Ingenuity® Pathway Analysis (IPA®) software 
predicted 104 target genes for miR-151b (Supplementary 
Table 1) while miRWalk analysis identified 1063 seed 
sequences (corresponding to 368 genes). There were 53 
predicted gene targets for miR-151b with a statistically 
significant relation identified in common for both 
softwares (Supplementary Figure 1). Afterwards, Network 
Analyst showed several of these predicted targets to be 
related to Cancer pathways (Figure 3).
DISCUSSION
UTUC is considered to have an unpredictable 
prognosis. In the present series, more than one third of 
the patients developed tumour progression and died from 
their cancer within four years of follow-up. Pathological 
stage and histological grade are the most commonly used 
prognostic factors for UTUC, but they are insufficient to 
accurately predict tumour progression. The identification 
of minimally invasive prognostic UTUC biomarkers would 
help to accurately estimate the progression risk at the time of 
diagnosis, and consequently to identify the most appropriate 
therapy for each individual patient. Furthermore, it may be 
useful for monitoring tumour progression after RNU.
Our group has prior experience in miRNA analysis 
from different types of urothelial cell carcinoma samples. 
On the one hand, we provided evidence that miRNAs 
can be used as prognostic biomarkers in UTUC in tissue 
samples [3, 4]. On the other, we showed that miRNAs 
can be useful diagnostic and prognostic biomarkers for 
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bladder cancer in urine samples [12, 18]. Here, we evaluate 
circulating miRNA in the bloodstream from UTUC patients 
as minimally invasive predictive biomarkers of tumour 
progression and patient survival.
It has been previously described that circulating 
miRNAs in the bloodstream may be used as disease 
markers due to their methodological advantages over gene 
expression assays. First, it is easier to obtain short mature 
serum miRNAs than long-chain serum mRNA, since 
they are more stable against nuclease degradation [19]. 
In addition, the average copy number of an individual 
miRNA has been estimated to be ~ 500 per cell, which 
may be higher than the average mRNA species [20]. 
Consequently, less total RNA is required for a miRNA 
than for an mRNA assay. Regarding the technology used to 
quantify miRNA expression, here we have used nCounter 
(NanoString Technologies). This system is a simple and 
cost-effective methodology that allows gene expression 
quantification in a multiplex format. In addition, it does 
not need any nucleic acid amplification and it provides 
more accurate miRNA quantification than PCR or 
microarray-based methods, especially in samples with 
low abundant and degraded RNA [21–23]. Actually, this 
system is already used in clinical settings for diagnostic as 
well as prognostic purpouses [24, 25].
Therefore, circulating miRNAs may be a potentially 
useful blood-based tool for monitoring human cancers 
or predicting tumour outcome. In the case of urothelial 
carcinoma, some diagnostic miRNAs have been identified 
in serum samples from bladder cancer patients [26, 27]. 
Figure 1: Heat map showing the 38 miRNAs differentially expressed between patients with progressing and non-
progressing UTUC (N=12). Red pixels correspond to a greater abundance of miRNA in the serum samples, whereas green pixels 
indicate lower miRNA levels. Rows represent individual miRNAs and columns represent experimental samples.
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Jiang X et al [28] evaluated miRNA expression in serum 
samples from muscle-invasive bladder tumour, and they 
found two miRNAs (miR-486-3p and miR-103a-3p) with 
prognostic value in these patients. In the case of UTUC, 
there are only few studies evaluating UTUC circulating 
miRNAs, and all of them have been focused on identifying 
Table 1: List of the 18 differentially expressed miRNAs and their FC values in the validation phase
miRNA p-value FC FDR (%)
hsa-miR-600 0.001 -2.32 2.07
hsa-miR-504-3p 0.002 -2.30 2.431
hsa-miR-1279 0.003 -2.29 2.712
hsa-miR-198 0.001 -2.28 2.141
hsa-miR-151b 0.003 -2.13 2.747
hsa-miR-499b-3p 0.010 -1.99 3.329
hsa-miR-937-3p 0.008 -1.94 3.199
hsa-miR-1909-3p 0.018 -1.87 3.995
hsa-miR-383-5p 0.031 -1.86 5.357
hsa-miR-376b-3p 0.024 -1.86 4.755
hsa-miR-924 0.039 -1.82 6.143
hsa-miR-1254 0.016 -1.82 3.846
hsa-miR-1204 0.041 -1.80 6.332
hsa-miR-1272 0.020 -1.77 4.185
hsa-miR-132-3p 0.032 -1.76 5.416
hsa-miR-614 0.044 -1.74 6.489
hsa-miR-1234-3p 0.042 -1.73 6.385
hsa-miR-199b-5p 0.037 -1.72 5.89
P-value = Student’s t test. Statistically significant FDR≤10%
Abbreviations: FC=Fold Change; FDR=False Discovery Rate.
Figure 2: Kaplan Meier curves for (A) tumour progression and (B) cancer-specific survival according to miR-151b expression values (N=33). 
Green line represents patients at low risk (expression cutoff≥4.21) and blue line represents patients at high risk (expression cutoff<4.21).
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diagnostic biomarkers. Kriebel et al., reported alterations in 
miRNA expression, both in serum (n=44) and tissue (n=47) 
samples from UTUC patients. They showed that circulating 
miR-141 may be useful as diagnostic biomarker [29]. Tao 
et al. using 46 serum samples from UTUC patients and 30 
controls identified a tenserum miRNA-based expression 
profile that was useful in discriminating between UTUC 
cases and controls [17]. However, as far as we could 
ascertain, this is the first study that shows differences in 
the miRNA expression profile between serum samples 
from progressing and non-progressing UTUC patients and 
identifies a prognostic circulating miRNA (miR-151b) that 
independently predicts tumour progression and cancer 
specific survival. Unfortunately, neither the diagnostic nor 
prognostic serum miRNAs identified in bladder cancer 
samples are shared with miRNAs found in serum UTUC 
samples, supporting the previous genetic differences found 
in both tumour types [30, 31].
In accordance with our results, down-regulation 
of circulating miR-151b is described in primary CNS 
lymphoma patients [32]. Furthermore, in silico analysis 
shows that one of the target genes of miR-151b, CCNE1, 
Figure 3: Network Analyst-derived protein–protein interactions network results. Network constructed with the 53 genes 
shared across most of data sets as seed proteins. Red nodes are most important interactions, followed by pink nodes and finally purple 
nodes. Nodes in blue represent those proteins interacting in Cancer pathways.
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is involved in T-cell signaling, cell-cycle, DNA-damage 
induced signaling and breast, pancreas, lung and prostate 
cancer pathways. Interestingly, CCNE1 has been 
previously suggested as a prognostic biomarker for UTUC 
[33]. Wu S et al. [34] demonstrated that over-expression of 
CCNE1 is associated with lower overall survival in UTUC 
patients, which is in concordance with our results showing 
down-regulation of miR-151b in progressing patients.
We are aware, however, that the study has some 
limitations. First, the total number of patients analyzed can 
be considered as low. It should be taken into account that 
UTUC is a rare disease, accounting only for 5-10% of all 
urothelial carcinomas, which makes it difficult to obtain 
large prospective series. Furthermore, we followed a very 
restrictive inclusion criterion, excluding all those patients 
having UTUC and other active neoplasms. Second, 
miRNA isolation from serum samples is challenging 
since the amount of circulating miRNA is low. Even so, 
we were able to analyze miRNA expression in all samples 
except two (informative specimen rate of 94%). Finally, 
the data reported warrants further prospective evaluation 
in carefully and specifically designed studies.
In conclusion, our results demonstrate that serum 
samples from progressive and non-progressive UTUC 
patients show a differential miRNA expression pattern. 
We also show that expression of miRNA-151b in serum 
samples significantly predicts progression and cancer-
specific survival in UTUC patients, indicating that it 
may be a novel potential minimally invasive biomarker 
for prognosis of UTUC patients. Although independent 
validation of the data is necessary, the identification of 
new circulating miRNAs associated with poor outcome 
in patients with UTUC may help tailor treatment and 
surveillance strategies in these patients.
Table 2: Pathological features of UTUC patients
Progressing UTUC
N (%)




Nº Patients 13 20 33
Gender
 Male 8 (62) 15 (75) 23 (70)
 Female 5 (38) 5 (25) 10 (30)
Tumor location
 Pelvis 5 14 19 (58)
 Ureter 7 5 12 (36)
 Both 1 1 2 (6)
Pathological Stage
 pTa 1 (8) 6 (30) 7 (21)
 pT1 1 (8) 4 (20) 5 (15)
 pT2 3 (23) 4 (20) 7 (21)
 pT3 6 (46) 6 (30) 12 (37)
 pT4 2 (15) 0 (0) 2 (6)
Histological Grade
 Low 2 (15) 4 (20) 6 (18)
 High 11 (85) 16 (80) 27 (82)
Metastasis
 Local 3 (24) - 3 (24)
 Distant 5 (37) - 5 (37)
 Local + Distant 2 (15) - 2 (15)
 Nodes 3 (24) - 3 (24)
Chemotherapy
 Adjuvant 9 (69) - 9 (69)
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MATERIALS AND METHODS
Patients and clinical samples
Prospective study including 35 UTUC patients 
who underwent radical RNU at the Hospital Clinic of 
Barcelona from January 2008 to August 2014. Finally, 33 
UTUC patients (12 progressing and 21 non-progressing) 
were analyzed. Consecutive patients with a minimum of 
36 months of follow-up were enrolled. Exclusion criteria 
were presence of another active neoplasm or absence 
of UTUC confirmation. Patients’ histopathological 
characteristics are summarized in Table 2. Histological 
Grade and Pathological Stage of the tumors were 
determined according to WHO criteria and TNM 
classification, respectively [35, 36]. Institutional Review 
Board approval and patients’ informed consents were 
obtained from all patients.
All patients were diagnosed by computed 
tomography (CT) scan and followed-up postoperatively 
with CT scan and cystoscopy at 3-month intervals for 
the first year, at 6-month intervals for the next 2 years, 
and annually thereafter. Tumours were considered as 
progressing when distant metastasis or pathological nodes 
were developed during follow-up.
This study was split into a two-stage approach with 
an initial discovery phase (training set) and a validation 
phase (testing set). Initial discovery phase included 12 
UTUC patients, 5 progressing [1 pT2, 3 pT3 and 1 pT4, 
all high grade (HG)] and 7 non-progressing (2 pTa, 1 pT2 
and 4 pT3, all HG). Validation phase comprised 21 UTUC 
patients, 8 progressing [1 pTa low grade (LG), 1 pT1 LG, 2 
pT2 HG, 3 pT3 HG and 1 pT4 HG] and 13 non-progressing 
(4 pTa LG, 4 pT1 HG, 3 pT2 HG and 2 pT3 HG).
Serum sample processing and RNA isolation
Whole blood samples were collected in the operating 
room before RNU in a BD Vacutainer 10mL sterile tube 
coated with silicone and micronized silica particles and stored 
at 4ºC. Blood was left to clot for a minimun of one hour and, 
within four hours, tubes were centrifuged for 15 minutes 
at 3500rpm, 4ºC. Serum was immediately transferred to a 
cryotube and stored in aliquots at -80ºC until use.
Total RNA was isolated from 500μL of serum 
aliquots using mirVana PARIS Kit (Thermosfisher 
Scientific) according to the manufacturer’s instructions. 
Before RNA isolation, 5μL at 200pM of five Spike-
In controls (ath-miR-159a, cel-miR-248, cel-miR-254, 
osa-miR-414 and osa-miR-442) were added to each 
sample. Total RNA was quantified with a NanoDrop1000 
(NanoDrop Technologies, Wilmington, DE, USA).
Expression analysis
Expression profiling of 800 human miRNAs from 
miRBase v3 was analyzed with the nCounter Human v3 
miRNA Expression Assay Kit (NanoString Technologies) 
following manufacturer’s instructions. Briefly, the assay 
uses molecular barcodes called nCounter Reporter Probes 
to detect microRNAs. The reaction involves a multiplexed 
hybridization of the specific probes to their target miRNA 
and an enzymatic purification to remove the unligated 
probes on the nCounter Prep Station. Data is finally 
collected by direct digital counting of the target molecules 
in each sample using the nCounter Digital analyzer. The 
assay contains positive and negative controls, reference 
genes and spike-in controls.
Five spike-in controls were used to compensate 
variations in RNA recovery between samples. Six 
established housekeeping miRNAs for serum already 
included in the assay (hsa-miR-16-5p, hsa-miR-484, hsa-
miR-126-3p, hsa-miR-191-5p, hsa-miR-93-5p and hsa-
miR-24-3p) were used to normalize microRNA expression 
levels [37–39]. After normalization, fold change 
expression between progressing and non-progressing 
patients was calculated using the moderate p-value (FDR)
of the limma-R package [40].
Statistical analysis
Univariate Cox regression analysis was performed 
on the established clinical prognosticators of UTUC 
(stage and grade) and the 18 differentially expressed 
miRNAs to examine its influence on tumor progression 
and cancer specific survival; afterwards, multivariate 
forward stepwise Cox regression analysis was performed 
on significant covariates. Statistical significance was 
established at a p-value of 0.05 and according to 95% 
confidence intervals (CI). miRNA expression was 
dichotomized using the median expression value of 
miR-151b (cutoff = 4.21). Thereafter, Kaplan-Meier 
curves were generated. SPSS 23.0 software was used for 
statistical analysis.
Pathway enrichment analysis
The biological targets of the miRNAs identified 
were investigated using IPA®. Interactions and networks 
between significant miRNAs and genes were mapped to 
pathways, regulators, diseases, and functions based on 
direct/indirect and experimentally validated targets.
The miRWalk software [41] was used to predict 
putative miRNA binding sites in target genes, in order 
to discover possible canonical altered pathways. Finally, 
Network Analyst [42] was used to determine protein-
protein interactions of the resulting genes from the 
previous analysis.
Abbreviations
RNU, Radical Nephroureterectomy; UTUC, Upper 
Tract Urothelial Carcinoma; CI, confidence interval; CT 
scan, computed tomography scan; LG, low grade; HG, 
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high grade; HR, hazard ratio; IPA, Ingenuity Pathway 
Analysis; miRNA, microRNA.
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